Swipe om te navigeren naar een ander artikel
The online version of this article (https://doi.org/10.1007/s11136-018-1992-3) contains supplementary material, which is available to authorized users.
Chronic hepatitis C infection and its treatment can considerably affect patients’ health-related quality-of-life (HRQoL). This study aimed to identify and summarise the current evidence base for health state utility values (HSUVs) in patients with chronic hepatitis C infection, generated using the EuroQol 5-dimensions (EQ-5D) questionnaire.
MEDLINE, Embase, the Cochrane Library and EconLit were searched from database inception through 31 August 2017. Eligible studies reported HSUVs elicited using the EQ-5D questionnaire in adults with chronic hepatitis C infection. Study quality and risk of bias were assessed.
Of 1480 records identified, 26 studies were included. The most commonly defined health states described different stages of chronic hepatitis C infection and specific liver-related disease states, including METAVIR score, compensated and decompensated cirrhosis, hepatocellular carcinoma and liver transplantation. Patients with higher METAVIR scores tended to have lower EQ-5D scores compared to patients with lower METAVIR scores. Patients that achieved sustained virologic responses tended to have higher EQ-5D scores compared to those that did not. A meta-analysis conducted on three studies confirmed that patients with decompensated cirrhosis have significantly lower HSUVs than patients with compensated cirrhosis [mean difference − 0.11 (95% CI − 0.19 to − 0.04)], implying worse HRQoL. However, there was not sufficient evidence to compare how different treatments for chronic hepatitis C infection affect EQ-5D scores.
This study provides a summary of EQ-5D HSUVs for patients with chronic hepatitis C infection, and demonstrates that clinically important disease stages associated with treatment decisions are associated with differences in HRQoL.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Supplementary material 1 (DOCX 23 KB)11136_2018_1992_MOESM1_ESM.docx
World Health Organization (2018). Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed July 19, 2018.
Negro, F., & Alberti, A. (2011). The global health burden of hepatitis C virus infection. Liver International, 31(s2), 1–3.
Manns, M., Wedemeyer, H., & Cornberg, M. (2006). Treating viral hepatitis C: Efficacy, side effects, and complications. Gut, 55(9), 1350–1359.
Seifert, L. L., Perumpail, R. B., & Ahmed, A. (2015). Update on hepatitis C: Direct-acting antivirals. World Journal of Hepatology, 7(28), 2829.
Ermis, F., & Tasci, E. S. (2015). New treatment strategies for hepatitis C infection. World Journal of Hepatology, 7(17), 2100.
Patrick, D. L., & Deyo, R. A. (1999). Generic and disease-specific measures in assessing health status and quality of life. Medical Care, 27, 217–232.
Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., et al. (2015). Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): A randomised, open-label phase 2 trial. The Lancet, 385(9973), 1075–1086.
European Medicines Agency (2005). Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products, https://www.ispor.org/workpaper/emea-hrql-guidance.pdf. Accessed July 19, 2017.
Kastien-Hilka, T., Abulfathi, A., Rosenkranz, B., Bennett, B., Schwenkglenks, M., Sinanovic, E. (2016). Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis—A systematic review of global literature with focus on South Africa. Health and Quality of Life Outcomes, 42(14), 1–13.
EuroQoL (2017). How to use EQ-5D. https://euroqol.org/eq-5d-instruments/. Accessed July 19, 2017.
National Institute of Health and Care Excellence (2013). Guide to the methods of technology appraisal 2013. https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed July 19, 2018.
Drummond, M. E., Sculpher, M. J., Torrance G. W., et al. (2005). Methods for the eocnomic evaluation of health care programmes (3rd ed.). Oxford: Oxford University Press.
Wee, H. L., Machin, D., Loke, W. C., Li, S. C., Cheung, Y. B., Luo, N., et al. (2007). Assessing differences in utility scores: A comparison of four widely used preference-based instruments. Value in Health, 10(4), 256–265.
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Annals of Internal Medicine, 151(4), 264–269.
EuroQoL. (2017). Search engine for EuroQol and EQ-5D-related material. https://euroqol.org/. Accessed Sept 2017.
Papaioannou, D., Brazier, J., & Paisley, S. (2010). NICE DSU Technical Support Document 9: The identification, review and synthesis of health state utility values from the literature. https://www.ncbi.nlm.nih.gov/books/NBK425822/pdf/Bookshelf_NBK425822.pdf. Accessed 12 Sept 2018.
Chong, C. A. K. Y., Gulamhussein, A., Heathcote, E. J., Lilly, L., Sherman, M., Naglie, G., et al. (2003). Health-state utilities and quality of life in hepatitis C patients. American Journal of Gastroenterology, 98(3), 630–638.
Bjornsson, E., Verbaan, H., Oksanen, A., Fryden, A., Johansson, J., Friberg, S., et al. (2009). Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian Journal of Gastroenterology, 44(7), 878–887. [ Multicenter Study]
Samp, J. C., Perry, R., Piercy, J., & Baran, R. W. (2014). Utility values of hepatitis C patients in France: Results by liver disease stage and treatment outcome. Value in Health, 17(3), A279. [ Conference Abstract]
Samp, J. C., Perry, R., Piercy, J., Wood, R., & Baran, R. W. (2015). Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France. Clinics and Research in Hepatology and Gastroenterology, 39(3), 307–314.
Custer, B., Vahidnia, F., Kessler, D., Leparc, G., Krysztof, D., Shaz, B., et al. (2014). Health-related quality of life in us blood donors with and without viral infections. Vox Sanguinis, 107, 97. [ Conference Abstract]
DeVecchis Wygant, G., Mo, L., Treitel, M., Bhore, R., & Torbeyns, A. (2016). EQ-5D results in Asian patients with HCV G1b receiving DCV + ASV who are IFN intolerant/ineligible. Hepatology International, 10(Suppl 1), S142.
Kaishima, T., Akita, T., Aikata, H., Chayama, K., & Tanaka, J. (2016). Cost-effectiveness analysis related to HCV treatment is possible to be estimated in each province. Hepatology International, 10(Suppl 1), S148–S149.
McDonald, S. A., Hutchinson, S. J., Palmateer, N. E., Allen, E., Cameron, S. O., Goldberg, D. J., et al. (2013). Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. Journal of Hepatology, 58(3), 460–466.
Nouvertne, D., Perry, R., & Milligan, G. (2014). Health-related quality of life and productivity impairment in chronic hepatitis C patients in Germany. Journal of Viral Hepatitis, 21, 34–35. [ Conference Abstract]
Pol, S., Chevalier, J., Branchoux, S., Perry, R., Milligan, G., & Gaudin, A. F. (2015). Health related quality of life and utility values in chronic hepatitis C patients: A cross-sectional study in France, the UK and Germany. Journal of Hepatology, 62, S606. [ Conference Abstract]
Nwankwo, C. U., Sung, A. H., & Pike, J. S. (2014). Self-reported health related quality of life of hepatitis C virus (HCV) genotype 1 patients with and without comorbid conditions. Value in Health, 17(7), A369–A370.
Schafer, A., Wittchen, H. U., Backmund, M., Soyka, M., Golz, J., Siegert, J., et al. (2009). Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy. Addiction, 104(4), 630–640.
Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 22(7), 1707–1716.
Schwarzinger, M., Cossais, S., Deuffic-Burban, S., Pol, S., Fontaine, H., Larrey, D., et al. (2015). EQ-5D utility index in French patients with chronic hepatitis C (CHC) infection: Severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage. Journal of Hepatology, 62, S605.
Scott, J., Rosa, K., Fu, M., Cerri, K., Peeters, M., Beumont, M., et al. (2014). Fatigue during treatment for hepatitis C virus: Results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases, 14(1), 465.
Stepanova, M., Nader, F., Cure, S., Bourhis, F., Hunt, S., & Younossi, Z. M. (2014). Patients’ preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Alimentary Pharmacology and Therapeutics, 40(6), 676–685.
Younossi, Z. M., Stepanova, M., Cure, S., Bourhis, F., Nader, F., & Hunt, S. L. (2014). Estimating health status using EQ5D for chronic hepatitis c (CH-C) patients treated with sofosbuvir (SOF) containing regimens. Journal of Hepatology, 1, S308. [ Conference Abstract]
Vargas, C. L., Espinoza, M. A., Giglio, A., & Soza, A. (2015). Cost effectiveness of daclatasvir/asunaprevir versus peginterferon/ribavirin and protease inhibitors for the treatment of hepatitis c genotype 1b Naive patients in Chile. PLoS ONE. 10(11), e0141660.
Vera-Llonch, M., Martin, M., Aggarwal, J., Donepudi, M., Bayliss, M., Goss, T., et al. (2013). Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Alimentary Pharmacology and Therapeutics, 38(2), 124–133.
Yeung, M. W., Young, J., Moodie, E., Rollet-Kurhajec, K. C., Schwartzman, K., Greenaway, C., et al. (2015). Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: A prospective cohort study. HIV Clinical Trials, 16(3), 100–110.
Wright, M., & Grieve, R. (2006). Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation. (Provisional abstract). Health Technology Assessment. 10, 1–250.
Vahidnia, F., Stramer, S. L., Kessler, D., Shaz, B., Leparc, G., Krysztof, D. E., et al. (2017). Recent viral infection in US blood donors and health-related quality of life (HRQOL). Quality of Life Research, 26(2), 349–357.
Gschwantler, M., Ferenci, P., Bauer, B., Laferl, H., Bamberger, T., Stauber, R., et al. (2016). Burden of disease in patients with chronic hepatitis C in the Austrian REAL Study. Hepatology, 63(Suppl 1), 466a–467a. [ Journal: Conference Abstract]
Huang, R., Rao, H., & Wei, L. (2017). Assessment of health-related quality of life and related factors in Chinese patients with chronic hepatitis C virus infection. Hepatology International, 11(Suppl 1), S558. [ Conference Abstract]
Kieran, J. A., Adams, R., Chin, J. L., Mushtaq, H., McCormick, P. A., McKiernan, S., et al. (2015). Health-state utilities for patients with chronic Hepatitis C infection. Irish Journal of Medical Science, 184(6 Suppl 1), S230. [ Conference Abstract]
Wygant, G., Mo, L., Treitel, M., & Zhao, Y. (2017). Patient reported outcomes in IFN/ribavirin intolerant/ineligible Asian patients from Mainland China receiving daclatasvir + asunaprevir for the treatment of HCV genotype 1b infection. Hepatology International, 11(Suppl 1), S1001–S1002. [ Conference Abstract]
MVH Group (1995). The measurement and valuation of health: Final report on the modelling of valuation tariffs. York: Centre for Health Economics, University of York.
Badia, X., Roset, M., Herdman, M., & Kind, P. (2001). A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Medical Decision Making, 21(1), 7–16.
ClinicalTrials.gov (2017). NCT01542788 (POSITRON). https://clinicaltrials.gov/ct2/show/NCT01542788. Accessed July 19, 2018.
ClinicalTrials.gov (2017). NCT01497366 (FISSION). https://clinicaltrials.gov/ct2/show/NCT01497366. Accessed July 19, 2018.
ClinicalTrials.gov (2017). NCT01604850 (FUSION). https://clinicaltrials.gov/ct2/show/NCT01604850. Accessed July 19, 2018.
ClinicalTrials.gov (2017). NCT01641640 (NEUTRINO). https://clinicaltrials.gov/ct2/show/NCT01641640. Accessed July 19, 2018.
Ara, R., & Brazier, J. (2008). Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value in Health, 11(7), 1131–1143.
Richardson, J., Iezzi, A., Khan, M. A., & Maxwell, A. (2012). Cross-national comparison of twelve quality of life instruments. MIC Paper, 2. https://www.aqol.com.au/papers/researchpaper78.pdf. Accessed 12 Sept 2018.
Rowen, D., Brazier, J., Tsuchiya, A., & Alava, M. H. (2012). Valuing states from multiple measures on the same visual analogue sale: A feasibility study. Health Economics, 21(6), 715–729.
Gray, A., Clarke, P., & Rivero-Arias, O. (2004). Estimating the association between SF-36 responses and EQ-5D utility values by direct mapping. In Health Economists Studying Group Meeting (HESG), Paris.
Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43, 203–220.
Zarate, V., Kind, P., Valenzuela, P., Vignau, A., Olivares-Tirado, P., & Munoz, A. (2011). Social valuation of EQ-5D health states: The Chilean case. Value in Health, 14(8), 1135–1141.
Fryback, D. G., Dunham, N. C., Palta, M., Hanmer, J., Buechner, J., Cherepanov, D., et al. (2007). US norms for six generic health-related quality-of-life indexes from the National Health Measurement Study. Medical Care, 45(12), 1162.
Dolan, P., Gudex, C., Kind, P., & Williams, A. (1995). A social tariff for EuroQol: Results from a UK general population survey. York: Centre for Health Economics University of York.
Longworth, L., Young, T., Ratcliffe, J., Bryan, S., & Buxton, M. (2001) Economic evaluation of the Transplantation Programme in England and Wales: An assessment of the costs of liver transplantation. Report to the Department of Health.
Bansback, N., Tsuchiya, A., Brazier, J., & Anis, A. (2012). Canadian valuation of EQ-5D health states: Preliminary value set and considerations for future valuation studies. PLoS ONE, 7(2), e31115.
Peasgood, T., & Brazier, J. (2015). Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values? Pharmacoeconomics, 33(11), 1101–1105.
- Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis
A. M. Buchanan-Hughes
L. A. Eddowes
- Springer International Publishing